Skip to content

BCBS Wyoming

Does BCBS Wyoming cover Zepbound?

Yes. BCBS Wyoming covers Zepbound for weight loss with prior authorization if your BMI is 30 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.

Policy document

  • Employer and ACA Marketplace: Covered with requirements. See the qualification pathways below.

Earliest policy review June 4, 2026. How we verify · Check your exact plan

Full requirements: Zepbound for Weight Loss (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Adult weight management (BMI ≥ 30)

All of:

  • Patient is an adult (18 years of age or over)
  • BMI ≥ 30 kg/m^2
  • Obesity is NOT restricted from coverage under the patient's benefit
  • Patient is new to therapy, new to Prime, or attempting a repeat weight loss course of therapy
  • Patient has been on a weight loss regimen of low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
  • Patient will NOT use the requested agent in combination with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
  • Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to the requested agent
  • Patient is currently on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications AND will continue it
  • Age is within FDA labeling for the requested indication OR there is support for use at patient's age

Plus any one of:

  • Patient has NOT tried a targeted weight loss agent (e.g., Saxenda, Wegovy, Zepbound) in the past 12 months
  • Patient tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND prescriber anticipates success with repeating therapy

Adult weight management (BMI ≥ 25 - Asian descent)

All of:

  • Patient is an adult (18 years of age or over)
  • Patient is of South Asian, Southeast Asian, or East Asian descent
  • BMI ≥ 25 kg/m^2
  • Obesity is NOT restricted from coverage under the patient's benefit
  • Patient is new to therapy, new to Prime, or attempting a repeat weight loss course of therapy
  • Patient has been on a weight loss regimen of low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
  • Patient will NOT use the requested agent in combination with another weight loss agent
  • Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to the requested agent
  • Patient is currently on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications AND will continue it
  • Age is within FDA labeling for the requested indication OR there is support for use at patient's age

Plus any one of:

  • Patient has NOT tried a targeted weight loss agent in the past 12 months
  • Patient tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND prescriber anticipates success with repeating therapy

Adult weight management (BMI ≥ 27 with comorbidity)

All of:

  • Patient is an adult (18 years of age or over)
  • BMI ≥ 27 kg/m^2
  • At least one weight-related comorbidity/risk factor/complication (e.g., hypertension, type 2 diabetes mellitus, obstructive sleep apnea, cardiovascular disease, dyslipidemia)
  • Obesity is NOT restricted from coverage under the patient's benefit
  • Patient is new to therapy, new to Prime, or attempting a repeat weight loss course of therapy
  • Patient has been on a weight loss regimen of low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
  • Patient will NOT use the requested agent in combination with another weight loss agent
  • Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to the requested agent
  • Patient is currently on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications AND will continue it
  • Age is within FDA labeling for the requested indication OR there is support for use at patient's age

Plus any one of:

  • Patient has NOT tried a targeted weight loss agent in the past 12 months
  • Patient tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND prescriber anticipates success with repeating therapy

Pediatric weight management (age 12-17)

All of:

  • Patient is pediatric (12 to 17 years of age)
  • Obesity is NOT restricted from coverage under the patient's benefit
  • Patient is new to therapy, new to Prime, or attempting a repeat weight loss course of therapy
  • Patient has been on a weight loss regimen of low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months
  • Patient will NOT use the requested agent in combination with another weight loss agent
  • Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
  • Patient does NOT have any FDA labeled contraindications to the requested agent
  • Patient is currently on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications AND will continue it
  • Age is within FDA labeling for the requested indication OR there is support for use at patient's age

Plus any one of:

  • BMI ≥ 95th percentile for age and sex
  • BMI ≥ 30 kg/m^2
  • BMI ≥ 85th percentile for age and sex AND at least one weight-related comorbidity/risk factor/complication (e.g., hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea)

Documentation to bring

  • Documentation of BMI ≥ 30 kg/m^2 (or ≥ 27 with comorbidity, or ≥ 25 if Asian descent, or BMI percentile for pediatric patients)
  • Documentation of 6-month weight loss regimen (low-calorie diet, increased physical activity, behavioral modifications)
  • Documentation of weight-related comorbidity if using the 27 kg/m^2 threshold
  • Documentation of ancestry if using the 25 kg/m^2 Asian threshold
  • Documentation that obesity is not restricted from coverage under the patient's benefit

Quantity limits

  • 2.5 MG/0.5 ML vial — 4 Vials per 180 days (84-day)
  • 5 MG/0.5 ML vial, 7.5 MG/0.5 ML vial, 10 MG/0.5 ML vial, 12.5 MG/0.5 ML vial, 15 MG/0.5 ML vial — 4 Vials per 28 days
  • 2.5 MG/0.5 ML autoinjector — 4 Pens per 180 days (84-day)
  • 5 MG/0.5 ML autoinjector, 7.5 MG/0.5 ML autoinjector, 10 MG/0.5 ML autoinjector, 12.5 MG/0.5 ML autoinjector, 15 MG/0.5 ML autoinjector — 4 Pens per 28 days
  • 2.5 MG/0.6 ML KwikPen — 1 Pen per 180 days (84-day)
  • 5 MG/0.6 ML KwikPen, 7.5 MG/0.6 ML KwikPen, 10 MG/0.6 ML KwikPen, 12.5 MG/0.6 ML KwikPen, 15 MG/0.6 ML KwikPen — 1 Pen per 28 days

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: For renewal (after 52 weeks on maximum-tolerated dose), patient must have achieved and maintained ≥ 5% weight loss from baseline. Patients with < 52 weeks on maximum-tolerated dose may also qualify without demonstrating weight loss. Renewal also requires: obesity not restricted from benefit, continuing current weight loss course of therapy, pediatric patients (12-17) must have current BMI ≥ 85th percentile for age and sex, not combining with another weight loss agent, maintaining low-calorie diet/increased physical activity/behavioral modifications, not combining with another GLP-1 agonist, and no FDA labeled contraindications.
  • Renewal: At least 52 weeks on therapy before the first renewal.

Not covered when

  • Combination with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical) not allowed
  • Combination with another GLP-1 receptor agonist (e.g., Saxenda, Wegovy, Zepbound, Bydureon, Byetta, Mounjaro, Ozempic, Rybelsus, Trulicity, Victoza) not allowed
  • Any FDA labeled contraindications to the requested agent
  • Obesity restricted from coverage under the patient's benefit

Policy note: Zepbound available as vials, autoinjectors, and KwikPens — all covered. For continuation after 52 weeks on maximum-tolerated dose, patient must demonstrate ≥ 5% weight loss from baseline. Patients with < 52 weeks on maximum-tolerated dose may qualify for renewal without demonstrating weight loss. Policy also allows approval if patient has another FDA labeled indication for the requested agent. This weight loss entry excludes the OSA pathway, which is captured separately.

Policy effective June 1, 2026 · verified June 4, 2026 · source: Wy Weight Management Paql Prog Sum · View policy document (PDF)

Open on its own page →

Full requirements: Zepbound for Obstructive Sleep Apnea (OSA) (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

OSA - Initial Approval (Zepbound only)

All of:

  • Diagnosis of obstructive sleep apnea (OSA)
  • Polysomnography (PSG) or home sleep apnea test performed
  • AHI ≥ 15 events/hour from baseline (prior to initiation of pharmacotherapy)
  • Requested agent is Zepbound
  • BMI ≥ 30 kg/m^2
  • Patient does NOT have craniofacial abnormalities that may affect breathing
  • Patient does NOT have diagnosis of Central or Mixed Sleep Apnea with mixed or central apneas/hypopneas ≥ 50%
  • Patient does NOT have diagnosis of Cheyne Stokes Respiration
  • Patient does NOT have diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia
  • Prescriber is a specialist (e.g., pulmonologist, sleep specialist) or has consulted with a specialist

Documentation to bring

  • Medical records confirming diagnosis of obstructive sleep apnea (OSA)
  • Polysomnography (PSG) or home sleep apnea test results showing AHI ≥ 15 events/hour at baseline
  • Documentation of BMI ≥ 30 kg/m^2
  • Documentation that patient does NOT have craniofacial abnormalities affecting breathing
  • Documentation that patient does NOT have Central or Mixed Sleep Apnea with ≥ 50% mixed or central apneas/hypopneas
  • Documentation that patient does NOT have Cheyne Stokes Respiration
  • Documentation that patient does NOT have Obesity Hypoventilation Syndrome or daytime hypercapnia
  • Documentation of specialist prescriber or specialist consultation (e.g., pulmonologist, sleep specialist)

Quantity limits

  • 2.5 MG/0.5 ML vial — 4 Vials per 180 days (84-day)
  • 5 MG/0.5 ML vial, 7.5 MG/0.5 ML vial, 10 MG/0.5 ML vial, 12.5 MG/0.5 ML vial, 15 MG/0.5 ML vial — 4 Vials per 28 days
  • 2.5 MG/0.5 ML autoinjector — 4 Pens per 180 days (84-day)
  • 5 MG/0.5 ML autoinjector, 7.5 MG/0.5 ML autoinjector, 10 MG/0.5 ML autoinjector, 12.5 MG/0.5 ML autoinjector, 15 MG/0.5 ML autoinjector — 4 Pens per 28 days
  • 2.5 MG/0.6 ML KwikPen — 1 Pen per 180 days (84-day)
  • 5 MG/0.6 ML KwikPen, 7.5 MG/0.6 ML KwikPen, 10 MG/0.6 ML KwikPen, 12.5 MG/0.6 ML KwikPen, 15 MG/0.6 ML KwikPen — 1 Pen per 28 days

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: Patient must demonstrate clinical benefit with the requested agent (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale). AHI baseline measurement and PSG/home sleep test are NOT re-required at renewal. Specialist/consultation requirement remains.

Not covered when

  • Craniofacial abnormalities that may affect breathing
  • Central or Mixed Sleep Apnea with mixed or central apneas/hypopneas ≥ 50%
  • Cheyne Stokes Respiration
  • Obesity Hypoventilation Syndrome or daytime hypercapnia
  • Any FDA labeled contraindications to the requested agent

Policy note: Policy does NOT require prior PAP/CPAP therapy trial for OSA indication. AHI threshold is ≥ 15 events/hour (moderate-to-severe OSA). At renewal, clinical benefit is required (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale) but repeat PSG/home sleep test is not explicitly required. Specialist (e.g., pulmonologist, sleep specialist) or specialist consultation required at both initial and renewal.

Policy effective June 1, 2026 · verified June 4, 2026 · source: Wy Weight Management Paql Prog Sum · View policy document (PDF)

Open on its own page →

Questions people ask
Does BCBS Wyoming cover Zepbound?
Yes. BCBS Wyoming covers Zepbound for weight loss with prior authorization if your BMI is 30 or higher, or 27 or higher with a related condition. Other policy requirements and your plan's benefits also apply.
How long does a Zepbound approval last with BCBS Wyoming?
Weight Loss — Applies to Employer and ACA Marketplace plans. Initial approval: 12 months. Renewal: every 12 months. Obstructive Sleep Apnea (OSA) — Applies to Employer and ACA Marketplace plans. Initial approval: 12 months. Renewal: every 12 months.
What does BCBS Wyoming require to renew Zepbound?
Weight Loss — Applies to Employer and ACA Marketplace plans. For renewal (after 52 weeks on maximum-tolerated dose), patient must have achieved and maintained ≥ 5% weight loss from baseline. Patients with < 52 weeks on maximum-tolerated dose may also qualify without demonstrating weight loss. Renewal also requires: obesity not restricted from benefit, continuing current weight loss course of therapy, pediatric patients (12-17) must have current BMI ≥ 85th percentile for age and sex, not combining with another weight loss agent, maintaining low-calorie diet/increased physical activity/behavioral modifications, not combining with another GLP-1 agonist, and no FDA labeled contraindications. At least 52 weeks on therapy before the first renewal. Obstructive Sleep Apnea (OSA) — Applies to Employer and ACA Marketplace plans. Patient must demonstrate clinical benefit with the requested agent (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale). AHI baseline measurement and PSG/home sleep test are NOT re-required at renewal. Specialist/consultation requirement remains.
How current is this information?
The oldest review date among the policies on this page is June 4, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under BCBS Wyoming: Mounjaro, Ozempic, Wegovy

Zepbound under other plans: Wyoming Medicaid, BCBS Alabama, BCBS Arizona, BCBS Arkansas, BCBS Massachusetts, BCBS Michigan, BCBS Minnesota, BCBS Nebraska

All insurance plans · All medications

Summary of BCBS Wyoming's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.